Study Shows BioCote Antimicrobial Technology Effective Against CRE
Antimicrobial solutions provider BioCote Ltd. has demonstrated their antimicrobial technology can eliminate over 99.9 percent of a type of Carbapenem-resistant Enterobactriaceae (CRE) Klebsiella pneumoniae (CRKP). This is the fourth multidrug-resistant bacteria against which BioCote has proven effective.
CRE are a family of bacteria which, over the past decade, have been causing increasing problems in healthcare environments around the world. CRE related infections most commonly occur amongst individuals who are hospitalised, critically ill or who require invasive devices such as ventilators as part of their healthcare. They are dangerous because they are resistant to the group of antibiotics known as carbapenems, which are recognized as being amongst the most powerful antibiotics.
BioCote Ltd, the antimicrobial specialists has spotted a gap in the market for technology to combat the CRE superbug. The independently-performed ISO 22196 test demonstrated that BioCotes antimicrobial technology eliminates over 99.9 percent of the bacterium CRE Klebsiella pneumoniae. These results also demonstrate that resistance to antibiotics in bacteria does not mean resistance to BioCote technology, and so BioCote remains an effective preventative against multi-drug resistant bacteria.
Richard Hasting, technical director at BioCote, says, We are always looking for ways in which our antimicrobial technology can solve a problem and support the healthcare industry. Multidrug-resistant pathogens are extremely worrying for the healthcare industry, and so the results from this test are very encouraging. Alongside good cleaning and disinfection procedures, BioCotes technology can help control antibiotic resistant bacteria in a healthcare environment. The development of new drugs to combat these infections is still necessary, but BioCote help to minimize the crisis by preventing the spread and survival of bacteria in the first place.
BioCote technology has already been proven to be effective against a wide range of bacteria and fungi. Other superbugs which BioCote has previously developed preventative antimicrobial technology against are methicillin-resistant Staphylococcus aureus, Vencomycin-resistant Enterococcus and extended spectrum beta lactamase-producing E. coli.
Â
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.
Invisible, Indispensable: The Vital Role of AHRQ in Infection Prevention
March 25th 2025With health care systems under strain and infection preventionists being laid off nationwide, a little-known federal agency stands as a last line of defense against preventable patient harm. Yet the Agency for Healthcare Research and Quality (AHRQ) is now facing devastating cuts—threatening decades of progress in patient safety.
